Second-line chemotherapy in recurrent small cell lung cancer: Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen)
- 31 May 2005
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 48 (2), 251-261
- https://doi.org/10.1016/j.lungcan.2004.10.016
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-upLung Cancer, 2003
- Recurrent small cell lung cancer: UpdateSeminars in Oncology, 2003
- Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-UpJournal of Clinical Oncology, 2002
- A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysisLung Cancer, 2000
- Management of Small Cell Lung CancerChest, 1999
- Second-line chemotherapy and its evaluation in small cell lung cancerCancer Treatment Reviews, 1999
- Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1991
- Second line chemotherapy in small cell lung cancerLung Cancer, 1989
- Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1987
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958